Challenges in Antibiotic R&D Calling for a Global Strategy Considering Both Short- and Long-Term Solutions

A recent analysis of antibiotics approved between 1999 and 2014, conducted by researchers at the Norwegian Institute of Public Health; the University of Oslo; the Center for Disease Dynamics, Economics & Policy (CDDEP); and Boston University, showed a lack of novelty and diversity regarding targ...

Full description

Saved in:
Bibliographic Details
Published inACS infectious diseases Vol. 5; no. 8; pp. 1265 - 1268
Main Authors Kållberg, Cecilia, Salvesen Blix, Hege, Laxminarayan, Ramanan
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 09.08.2019
Online AccessGet full text

Cover

More Information
Summary:A recent analysis of antibiotics approved between 1999 and 2014, conducted by researchers at the Norwegian Institute of Public Health; the University of Oslo; the Center for Disease Dynamics, Economics & Policy (CDDEP); and Boston University, showed a lack of novelty and diversity regarding target pathogens and indications and a failure to address the most urgent resistance threats, including resistant Gram-negative bacteria. A global research and development strategy should incentivize development of broad-spectrum antibiotics for critically ill patients, as well as therapeutic alternatives to antibiotics, decreasing our dependence on traditional, small-molecule antibiotics.
ISSN:2373-8227
2373-8227
DOI:10.1021/acsinfecdis.9b00076